perenostobart

Home
Ligands
perenostobart

GtoPdb Ligand ID: 12103

Synonyms: SRF-617 | SRF617

Comment: Perenostobart is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1/CD39). Based on analysis using the amino acid (aa) sequences provided in the INN documentation and patented aa sequences (via NCBI Blast: protein), perenostobart would appear to map to Surface Oncology's clinical lead anti-CD39 mAb SRF617. Surface Oncology claim anti-CD39 mAbs in patent US10738128B2 [1]. SRF617 is a fully human mAb that was designed to inhibit the enzymatic activity of ENTPD1/CD39.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Chappel S, Lake A, Warren M, Dulak A, Devereaux E, Holland PM, Zaidi T, Rausch M, Prinz B, Nielson NP et al.. (2020) Antibodies that bind CD39 and uses thereof. Patent number: US10738128B2. Assignee: Surface Oncology Inc. Priority date: 14/03/2018. Publication date: 11/08/2020.

References

1. Chappel S, Lake A, Warren M, Dulak A, Devereaux E, Holland PM, Zaidi T, Rausch M, Prinz B, Nielson NP et al.. (2020)
Antibodies that bind CD39 and uses thereof.
Patent number: US10738128B2. Assignee: Surface Oncology Inc. Priority date: 14/03/2018. Publication date: 11/08/2020.